Brokers Set Expectations for FibroGen, Inc.'s Q3 2022 Earnings (NASDAQ:FGEN)
Brokers Set Expectations for FibroGen, Inc.'s Q3 2022 Earnings (NASDAQ:FGEN)
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities research analysts at Jefferies Financial Group increased their Q3 2022 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, August 9th. Jefferies Financial Group analyst M. Yee now forecasts that the biopharmaceutical company will earn ($0.84) per share for the quarter, up from their prior estimate of ($0.98). The consensus estimate for FibroGen's current full-year earnings is ($3.24) per share. Jefferies Financial Group also issued estimates for FibroGen's Q4 2022 earnings at ($0.86) EPS, FY2022 earnings at ($3.18) EPS and FY2023 earnings at ($3.36) EPS.
FibroGen，Inc.(纳斯达克：FDEN-GET评级)-杰富瑞金融集团的股票研究分析师在8月9日星期二发布给客户和投资者的一份研究报告中，上调了他们对FibroGen股票2022年第三季度每股收益的预期。杰富瑞金融集团(Jefferies Financial Group)分析师M.Yee现在预测，这家生物制药公司本季度的每股收益将为0.84美元，高于此前预测的0.98美元。对FibroGen目前全年收益的普遍预期为每股3.24美元。杰富瑞金融集团还发布了对FibroGen 2022财年第四季度每股收益(0.86美元)、2022财年每股收益(3.18美元)和2023财年每股收益(3.36美元)的估计。
Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of FibroGen from a "buy" rating to a "hold" rating in a research note on Wednesday. The Goldman Sachs Group reduced their price target on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a research report on Tuesday, May 24th.
其他股票研究分析师也发布了有关该股的报告。在周三的一份研究报告中，StockNews.com将FibroGen的股票评级从“买入”下调至“持有”。5月24日，高盛夫妇将FibroGen的目标价从9.00美元下调至8.00美元，并在周二的一份研究报告中为该公司设定了“卖出”评级。
FibroGen Stock Up 3.1 %
FibroGen股价上涨3.1%
FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to the consensus estimate of $36.15 million. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. FibroGen's quarterly revenue was up 22.3% on a year-over-year basis. During the same period last year, the company earned ($1.45) earnings per share.
FibroGen(纳斯达克代码：FDEN-GET Rating)上一次公布季度收益数据是在8月8日星期一。这家生物制药公司公布了该季度每股收益(EPS)(0.78美元)，比分析师普遍预期的(0.94美元)高出0.16美元。该业务本季度的收入为2981万美元，而普遍预期为3615万美元。FibroGen的净资产回报率为负100.51%，净利润率为负83.64%。FibroGen的季度营收同比增长22.3%。去年同期，该公司每股收益为1.45美元。
Institutional Investors Weigh In On FibroGen
机构投资者对FibroGen的看法
A number of large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. grew its stake in FibroGen by 235.9% in the 4th quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after buying an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in FibroGen during the 4th quarter worth approximately $21,862,000. Federated Hermes Inc. boosted its stake in FibroGen by 84.1% in the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP grew its holdings in FibroGen by 24.8% in the 4th quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after buying an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after buying an additional 748,230 shares during the period. Institutional investors own 77.35% of the company's stock.
一些大型投资者最近增持或减持了该公司的股份。72Point72Asset Management L.P.在第四季度增持了235.9%的FibroGen股份。Point72 Asset Management L.P.在上个季度额外购买了2,621,494股后，现在拥有这家生物制药公司3,732,594股票，价值52,630,000美元。Soleus Capital Management L.P.在第四季度收购了FibroGen的新股份，价值约21,862,000美元。联合爱马仕公司在第一季度增持了84.1%的FibroGen股份。联合爱马仕公司目前持有这家生物制药公司2,395,883股股票，价值28,799,000美元，在此期间又购买了1,094,403股。First Trust Advisors LP在第四季度增持了24.8%的FibroGen。First Trust Advisors LP现在拥有这家生物制药公司5,317,613股股票，价值74,978,000美元，上个季度又购买了1,055,536股。最后，Assenagon Asset Management S.A.在第二季度将其在FibroGen的头寸增加了333.0%。Assenagon Asset Management S.A.现在持有这家生物制药公司972,901股票，价值10,274,000美元，在此期间又购买了748,230股票。机构投资者持有该公司77.35%的股份。
FibroGen Company Profile
FibroGen公司简介
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物制药公司，发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat，该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发，并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 值得关注的两场重要的零售股大战
- MarketBeat：回顾中的一周2012-8-8
- 什么是WallStreetBets，他们的目标是什么股票？
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗？
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。